Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (343)	11/29/1999 6:41:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1834

heh heh heh.... beat ya! market cap 270M. research premium 225M. cheap, very, very cheap. >> My particular thanks to Rick, Miljenko and others for this one << Dr. Zuanic and I made a deal..... he'd do all the work, and I'd take all the credit. Right, MZ? - vbg - Saw a very good post by Dr. Tracy at Yahoo (yes, I have sinned again) the other day. You lurking, Harry? Want to cut and paste?

To: Biomaven who wrote (343)	11/29/1999 6:58:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 1834

I would like to thank Rick and MZ as well. I had visited NBIX in June of 1998 and was very impressed with Lyons, the scientific talent (from the point of view of a non-scientist--of course-- but who has visited about 15 other biotechs) and what they were trying to accomplish. However, I thought it was too early to buy so I began following the company and the comments from MZ and Rick here on SI. Their comments kept me interested. During the summer, I accumulated a very nice position (for me anyway) as they frequently reminded us of the great value the market was then ignoring in the lower tier biotechs. Great job gentlemen! Walter